Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242506 | 0.69 | CES1 (0.54) | CES1ALDH1A1TDP1SRCCES2 | |
| SCHEMBL6368612 | 0.69 | MGLL (0.44) | ALDH1A1HSP90AA1ATMTLR9PKM | |
| SCHEMBL252920 | 0.69 | CES1 (0.54) | CES1ALDH1A1TDP1SRCCES2 | |
| SCHEMBL1079930 | 0.69 | CES1 (0.54) | CES1ALDH1A1TDP1SRCCES2 | |
| SCHEMBL240232 | 0.69 | MGLL (0.44) | ALDH1A1HSP90AA1ATMTLR9PKM | |
| SCHEMBL562162 | 0.69 | CES1 (0.54) | CES1ALDH1A1TDP1SRCCES2 | |
| SCHEMBL36374 | 0.68 | CES1 (0.48) | CES1ALDH1A1TDP1SRCPTPN1 | |
| SCHEMBL1667516 | 0.68 | GRM5 (0.40) | CES1ALDH1A1MGLL | |
| SCHEMBL972914 | 0.67 | CES1 (0.57) | CES1ALDH1A1TDP1SRCPTPN1 | |
| SCHEMBL20503786 | 0.67 | CES1 (0.52) | CES1ALDH1A1TDP1SRCCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | claimed |
| EP-2315771-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2011-05-04 | — | — | EP | claimed |
| WO-2010006343-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-14 | — | — | WO | claimed |
| EP-0996455-B1 | ALPHA-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2009-12-16 | — | — | EP | claimed |
| EP-3768780-A1 | AZACYANINE DYES AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019180475-A1 | AZACYANINE DYES AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3013365-B1 | RM2 ANTIGENS AND USE THEREOF | ACADEMIA SINICA (TW) | 2019-06-05 | — | — | EP | disclosed |
| US-10086054-B2 | RM2 antigens and use thereof | ACADEMIA SINICA (TW) | 2018-10-02 | — | — | US | disclosed |
| US-9981030-B2 | Glycan conjugates and use thereof | ACADEMIA SINICA (TW) | 2018-05-29 | — | — | US | disclosed |
| US-9598466-B2 | Glycopeptide constructs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160193310-A1 | RM2 ANTIGENS AND USE THEREOF | ACADEMIA SINICA | 2016-07-07 | — | — | US | disclosed |
| EP-3013347-A1 | GLYCAN CONJUGATES AND USE THEREOF | Academia Sinica (TW) | 2016-05-04 | — | — | EP | disclosed |
| US-20030153492-A1 | Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-08-14 | — | — | US | disclosed |
| EP-0459978-B1 | CLASS I MHC MODULATION OF SURFACE RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0459978-A4 | CLASS I MHC MODULATION OF SURFACE RECEPTOR ACTIVITY | — | 1992-10-07 | — | — | EP | disclosed |
| US-5073540-A | Polypeptide sequence for regulating surface membrane receptor response, insulin, epidermal growth factor | RECEPTRON (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0459978-A1 | CLASS I MHC MODULATION OF SURFACE RECEPTOR ACTIVITY. | UNIV CALIFORNIA (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990010016-A1 | CLASS I MHC MODULATION OF SURFACE RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-09-07 | — | — | WO | disclosed |
| EP-0274824-A1 | Novel lipid-protein compositions and articles and methods for their preparation | Ribi, Hans O. (US) | 1988-07-20 | — | — | EP | disclosed |
| US-4144131-A | COUPLING, REACTION OF NUCLEOPHILIC AND ELECTROPHILIC GROUPS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193310-A1 | RM2 ANTIGENS AND USE THEREOF | LGALS2, MAN2B2, GALNT2 | CES1 3704/4885ALDH1A1 3794/4885HSP90AA1 3446/4885 |
| US-20030153492-A1 | Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof | B3GAT3, SIGLEC7, STT3A | CES1 836/4885ALDH1A1 1798/4885HSP90AA1 1399/4885 |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, MICA, SIGLEC7 | CES1 1672/4885ALDH1A1 3709/4885HSP90AA1 1142/4885 |
| US-10086054-B2 | RM2 antigens and use thereof | MAN2B2, LGALS2, GALNT2 | CES1 3646/4885ALDH1A1 4089/4885HSP90AA1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.